http://clinicaltrials.gov/ct2/show/N...+cancer&rank=2
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), April 2008
First Received: April 15, 2008 Last Updated: October 8, 2008
History of Changes
Sponsored by:
London Regional Cancer Program at London Health Sciences Centre
Information provided by: National Cancer Institute (NCI) ClinicalTrials.gov Identifier: NCT00659568
Purpose RATIONALE: Metformin and temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of metformin when given together with temsirolimus in treating patients with metastatic or unresectable solid tumor or lymphoma.
Condition Intervention Phase Breast Cancer
Endometrial Cancer
Kidney Cancer
Lung Cancer
Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific
Drug: metformin hydrochloride
Drug: temsirolimus
Phase 1
Other Metformin studies:
http://clinicaltrials.gov/ct2/result...tformin+cancer